Articles

Baucus health reform bill would stick Indiana companies with fees

The health reform bill sponsored by U.S. Sen. Max Baucus, D-Mont., would help pay for expanded health insurance coverage
by levying fees of $13 billion a year on the health care industry. The fees would deliver a hefty bill to just
about all of Indiana’s major health care companies. But how they’re reacting to the fees is all over the map.

Read More

Lilly agrees to settle more state Zyprexa suits

Eli Lilly and Co. has agreed to confidential terms to settle lawsuits brought by seven states alleging the company illegally
marketed bestselling antipsychotic drug Zyprexa, Bloomberg News reported today.

Read More

Lilly sells constipation drug to Adolor

Biotechnology company Adolor Corp. said yesterday that it bought exclusive worldwide rights to Eli Lilly and Co.’s OpRA
III drug candidate, which has a range of potential uses.

Read More

Lilly: Alimta improves lung-cancer survival time

Indianapolis-based Eli Lilly and Co. announced today that a clinical trial showed lung cancer patients treated with Lilly
drug Alimta lived about three months longer than those who received the best available care.

Read More

UPDATE: Pipeline challenges force Lilly restructuring moves

Since John Lechleiter was named CEO 18 months ago, he’s bet that Eli Lilly and Co. could face down its looming patent challenges
by launching innovative new medicines. Today’s announcement of 5,500 job cuts by the end of 2011 and a restructuring of the
company’s business units ups the ante on that bet, while indicating that it isn’t working yet.

Read More

Lilly reorganization to cut 5,500 positions over 2 years

Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue
from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central
Indiana. But with
13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.

Read More

Study weakens Lilly’s fight against price controls

Eli Lilly and Co. and its peers might be back in Congress’ sights as lawmakers hunt for more ways to cut health care
costs. A new study in the influential Health Affairs journal concludes that European drugmakers operating
in markets with pharmaceutical price controls have produced proportionally more innovations than their U.S. counterparts.

Read More

Lilly paid doctors to prescribe Zyprexa, notes say

Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers’ program in exchange for prescribing the
antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.

Read More

Lilly spent $3.6M on lobbying in second quarter

Drugmaker Eli Lilly and Co. spent nearly $3.6 million in the second quarter lobbying the federal government on health care
reform and trademark issues, among other topics, according to a recent disclosure form.

Read More

Lilly drops osteoporosis pipeline drug

Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating
the company’s attempts to find revenue before losing patent protection on its bestseller.

Read More

Lilly pays $224,000 to area doctors

It’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But
Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first
quarter.

Read More